Through mapping cancer type-specific in silico KMT2D GI networks, we revealed several SL candidates, namely NDUFB4, MDM2, TUBA1B, and WRN, that encode targets of existing and in-development therapeutics, making them potentially viable drug targets in cancers harbouring KMT2DLOF alterations. This evidence concerns the gene TUBA1B and cancer.